Synthon, Perrigo gain US FDA nod for generic allergy drug, winning first-to-file status
This article was originally published in Scrip
Perrigo's shares got a slight 2.1% boost, or $1.80, on 18 May after its partner Synthon Pharmaceuticals won approval from the US FDA on their abbreviated new drug application (ANDA) for Levocetirizine solution, a generic version of UCB's Xyzal, a histamine H1-receptor antagonist indicated for the relief of symptoms associated with seasonal and perennial allergic rhinitis and as a treatment for uncomplicated skin manifestations of chronic idiopathic urticaria.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.